Stockreport

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial [Yahoo! Finance]

CERo Therapeutics Holdings, Inc.  (CERO) 
PDF Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- [Read more]